美多芭联合普拉克索对帕金森病患者血清miR-124、miR-137表达和非运动症状的影响  

Effects of medoba combined with prampexole on miR-124,miR-137 and non-motor symptoms in patients with Parkinson's disease.

作　　者：童琴 程雪[2] 蔡银柜 李东 TONG Qin;CHENG Xue;CAI Yin-gui(Department of Psychiatry,Qianjiang Central Hospital,Chongqing 409000,China;Department of Gerontology,Chongqing Mental Health Center,Chongqing 401147,China;Department of Anesthesiology and Surgery,Chongqing Qianjiang Central Hospital,Chongqing 409000,China.)

机构地区：[1]重庆市黔江中心医院精神医学科,重庆409000 [2]重庆市精神卫生中心老年科,重庆401147 [3]重庆市黔江中心医院麻醉手术科,重庆409000 [4]重庆医药高等专科学校附属第一医院普外科,重庆400000

出　　处：《临床和实验医学杂志》2021年第18期1974-1977,共4页Journal of Clinical and Experimental Medicine

基　　金：重庆市卫生计生委医学科研项目(编号:2016MSXM122)。

摘　　要：目的探究美多芭联合普拉克索治疗帕金森病(PD)的疗效及对血清miR-124、miR-137表达和非运动症状的干预效果。方法采用回顾性研究方法,选取重庆市黔江中心医院收治的116例PD患者,按给药方案不同分组,对照组58例给予美多芭治疗,观察组58例在此基础上联合普拉克索治疗,均治疗3个月。比较2组临床疗效、血miR-124、miR-137表达和非运动症状评价量表(NMSS)评分。结果观察组治疗总有效率(91.4%)明显高于对照组(79.3%),差异有统计学意义(P<0.05)。观察组治疗3个月后的血miR-124表达(0.87±0.08)明显高于对照组(0.72±0.05),而血miR-137表达(1.41±0.13)明显低于对照组(1.76±0.15),差异均有统计学意义(P<0.05)。观察组治疗3个月后NMSS病情严重程度评分[(33.02±3.71)分]明显低于对照组[(45.39±3.16)分],而发生频率评分[(35.31±6.69)分]明显低于对照组[(50.28±5.87)分],差异均有统计学意义(P<0.05)。结论与单用美多芭治疗相比,美多芭联合普拉克索治疗PD的疗效更为确切,通过上调miR-124表达,下调miR-137表达,以助于控制非运动症状。Objective To explore the efficacy of Medopa combined with pramipexole in the treatment of Parkinson's disease(PD)and the intervention effect on serum miR-124,miR-137 expression and non-motor symptoms.Methods Using retrospective research methods,116 patients with PD admitted to Chongqing Qianjiang Central Hospital were selected and grouped according to different dosing schedules.Fifty eight patients in the control group were treated with metoprolate,and 58 patients in the observation group were treated with pramipexole on this basis.Both were treated for 3 months.To compare the clinical efficacy,blood miR-124,miR-137 expression and non-motor symptom evaluation scale(NMSS)scores between the two groups.Results The total effective rate of treatment in the observation group(91.4%)was significantly higher than that in the control group(79.3%),and the difference was statistically significant(P<0.05).The level of blood miR-124 expression in the observation group(0.87±0.08)after 3 months treatment was significantly higher than that in the control group(0.72±0.05),while the level of blood miR-137 expression(1.41±0.13)was significantly lower than that in the control group(1.76±0.15),and the differences were statistically significant(P<0.05).After 3 months treatment,the NMSS severity score in the observation group[(33.02±3.71)points]was significantly lower than that in the control group[(45.39±3.16)points],the occurrence frequency score[(35.31±6.69)points]was significantly lower than that in the control group[(50.28±5.87)points],the differences were statistically significant(P<0.05).Conclusion Compared with treatment with Madopar alone,the efficacy of Madopar combined with pramipexole in the treatment of PD is more accurate.By up-regulating the expression of miR-124 and down-regulating the expression of miR-137,it helps to control non-motor symptoms.

关 键 词：帕金森病 美多芭 普拉克索 miR-124 miR-137 非运动症状 

分 类 号：R742.5[医药卫生—神经病学与精神病学]